luliconazole

(loo-li-kon-a-zole) ,

Luzu

(trade name)

Classification

Therapeutic: antifungals
Pharmacologic: azoles

Pregnancy Category: C

Indications

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action

Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.

Antifungal action.

Therapeutic effects

Resolution of dermal fungal infection.

Active against Trichyphyton rubrum and Epidermpophyton floccosum.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.

Distribution: Unknown.

Protein Binding: >99%

Metabolism and Excretion: Unknown.

Half-life: unk

Time/action profile (improvement/resolution of infection)

ROUTE	ONSET	PEAK	DURATION
top	unk	3–4 wk†	unknown

†Following initiation of treatment.

Contraindications/Precautions

Contraindicated in: None noted;

Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies any fetal risks; Lactation: Use cautiously in breast feeding women. Pediatric: Safe and effective use in children <18 yr not established.

Adverse Reactions/Side Effects

Dermatologic

application site reactions

Interactions

Drug-Drug interaction

May inhibit the activity of the CYP3A4 and CYP2C19 enzymes.

Route/Dosage

Topical (Adults) Interdigital tinea pedisApply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporisApply to affected and surrounding areas once daily for one week.

Availability

Topical cream: 1%

Nursing implications

Nursing assessment

Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

Consult health care professional for proper cleansing technique before applying medication.
Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
- For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
- Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in skin irritation and resolution of infection.

References in periodicals archive ?

The newer topical azoles still under trial include sertaconazole, dapaconazole and luliconazole with effectiveness against malassezia species in PV13,14 Another option that requires further work is to combine more than one topical agents and see if there is an increased efficacy.

COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR

He noted that two topical agents approved for tinea pedis--naftifine 2% cream or gel and luliconazole 1% cream--are effective as once-daily therapy for 2 weeks, a considerably briefer regimen than with other approved topicals.

Best bets for topical toenail fungus therapy

Comparison of safety and efficacy of luliconazole and other antifungal agents.

Comparative study of the efficacy and safety of topical antifungal agents clotrimazole versus sertaconazole in the treatment of tinea corporis/cruris

Tsuboi, "Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis," Antimicrobial Agents and Chemotherapy, vol.

In Vivo Evaluation of Galla chinensis Solution in the Topical Treatment of Dermatophytosis

A good option in diabetic patients is luliconazole (Luzu), which is active against Trichophyton rubrum--the most common causative organism--and has the advantage of simplicity: The regimen is once-daily treatment for 2 weeks, much shorter than for many other topical antifungals, Dr.

Fungal foot infections risky in diabetes patients

Terbinafine, Ketoconazole, Fluconazole and Luliconazole.

Diagnosis and management of trichophyton verrucosum in ruminants a report of 4 animals

Luliconazole is an azole drug, meaning it is broad spectrum and kills dermatophytes, yeast, and molds.

Two antifungals shorten tinea pedis treatment time

Luliconazole (Luzu), an azole anti-fungal, is a cream used for the treatment of tinea pedis, tinea cruris, and tinea corporis.

Drugs approved in 2013

Topica gets USD27m financing to advance luliconazole studies

Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

FDA ACCEPTS TOPICA'S LULICONAZOLE IND FOR CLINICAL TRIALS

For tinea pedis, naftifine 2% and luliconazole 1% are new agents, both administered for relatively short courses, that may foster greater adherence